RedShift BioAnalytics Closes $11.0M Series C Financing

RedShift-BioAnalyticsRedShift BioAnalytics, Inc., a Burlington, MA-based provider of bioanalytical instrumentation for the research, development and manufacturing of protein therapeutic drugs, closed a $11.0m Series C financing.

The round was co-led by Waters Corporation (NYSE: WAT) and Technology Venture Partners.

The company will use the funds to accelerate the commercialization of its biotechnology instrument platform in 2017.

Led by Chip Marshall, CEO, RedShift BioAnalytics has developed a bioanalytical instrument that combining innovative lasers, microfluidics, and analytical technologies to provide five critical measurements in the development of protein-based drugs: quantitation, structure, stability, aggregation and similarity.



Join the discussion